Decanoic Octanoic Acid Ratio for Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for epilepsy, such as the ketogenic diet, often have adverse side effects and limited efficacy, and there is a need to understand the role of medium chain fatty acids in seizure control, particularly regarding AMPA receptor inhibition.
Innovation Solution
A composition with a specific ratio of decanoic acid to octanoic acid (70:30 to 90:10 wt/wt) is used to inhibit AMPA receptors, which are involved in seizure generation and propagation, offering a potential therapeutic approach for epilepsy and other conditions like ALS, cancer, and Alzheimer's Disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the ketogenic diet is used to treat epilepsy, then seizure control is improved, but adverse gastro-intestinal side effects and high attrition rate occur
Solution Approach 1:
The patent extracts and isolates the specific therapeutic component (decanoic acid) from the complex ketogenic diet formulation. By identifying decanoic acid as the primary anti-seizure agent and formulating it as a standalone composition with optimized concentration ranges (0.1-10 mM), the invention separates the beneficial anti-epileptic effect from the harmful gastro-intestinal side effects associated with the full ketogenic diet regimen.
Solution Approach 2:
The patent applies parameter changes by optimizing the concentration of decanoic acid within specific ranges (0.1-10 mM) and adjusting the ratio of decanoic acid to other medium-chain fatty acids. This precise parameter control allows achievement of therapeutic efficacy while minimizing toxic effects and gastro-intestinal disturbances that occur with higher concentrations or unoptimized formulations.
2Ease of operation
If conventional anti-convulsive medications are used, then epilepsy management is achieved, but minimal effect on seizure activity occurs in many patients
Solution Approach 1:
The patent introduces decanoic acid as an intermediary substance that mediates between conventional treatment approaches and ketogenic diet effects. As a medium-chain fatty acid metabolite, it acts as a biochemical intermediary that can be administered orally with better tolerability while achieving AMPA receptor inhibition and seizure control comparable to or exceeding conventional anti-convulsive medications.
3Reliability
If MCT ketogenic diet is used, then effective therapeutic approach for drug resistant epilepsy is achieved, but high attrition rate due to difficulty to tolerate occurs
Solution Approach 1:
The patent employs a simplified, standardized formulation of decanoic acid that can be administered as a discrete, controlled-dose composition rather than requiring adherence to a complex, long-term ketogenic diet regimen. This disposable-like approach to treatment (fixed composition, defined dosage) improves patient compliance and reduces attrition while maintaining therapeutic effectiveness.
Data Source
AI summary
A composition comprising a decanoic acid to octanoic acid ratio of 70:30 to 90:10 wt/wt for use in treating epilepsy or controlling epileptic seizures.